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Izabel Patik1, Virág Székely1, Orsolya Német1, Áron Szepesi2, Nóra Kucsma1, György Várady2, 
Gergely Szakács1,3, Éva Bakos1 & Csilla Özvegy-Laczka1
Organic Anion-Transporting Polypeptides are multispecific membrane proteins that regulate the 
passage of crucial endobiotics and drugs across pharmacological barriers. OATP1B1 and OATP1B3 
have been described to play a major role in the hepatic uptake of statins, antivirals and various 
chemotherapeutics; whereas the pharmacological role of the ubiquitously expressed OATP2B1 is 
less well characterized. According to current industry standards, in vitro testing for susceptibility to 
OATP1B1 and 1B3 mediated transport is recommended for drug candidates that are eliminated in 
part via the liver. Here we show that human OATP1B1, 1B3 and 2B1 transport a series of commercially 
available viability dyes that are generally believed to be impermeable to intact cells. We demonstrate 
that the intracellular accumulation of Zombie Violet, Live/Dead Green, Cascade Blue and Alexa Fluor 
405 is specifically increased by OATPs. Inhibition of Cascade Blue or Alexa Fluor 405 uptake by known 
OATP substrates/inhibitors yielded IC50 values in agreement with gold-standard radioligand assays. 
The fluorescence-based assays described in this study provide a new tool for testing OATP1B/2B1 drug 
interactions.
Human Organic Anion-Transporting Polypeptides (OATPs) encoded by the SLCO genes mediate the cellular 
uptake of large organic, amphipathic molecules1,2. At least four members of the family, OATP1A2, 1B1, 1B3 
and 2B1 are multispecific transporters that, besides the transport of endogenous substrates (bilirubin, bile acids 
and hormones), also promote the cellular uptake of pharmacologically relevant molecules. OATP1B1 and 1B3 
are almost exclusively expressed in the sinusoidal membranes of hepatocytes where they regulate the hepatic 
uptake of bile acids and bilirubin. Simultaneous mutations in the SLCO1B1 and 1B3 genes result in Rotor syn-
drome, characterized by increased serum bilirubin levels3. Additionally, OATP1B1 and 1B3 are key determinants 
of the hepatic clearance of widely prescribed medications (e.g. statins, antivirals) and also of chemotherapeutics 
including docetaxel, irinotecan and cisplatin4,5. Altered function of OATP1B1 and 1B3 due to single nucleotide 
polymorphisms (SNPs), drug-drug or drug-food interactions or disease conditions influences the in vivo effi-
cacy of drugs6,7. Co-administration of OATP1B substrate drugs may cause unexpected toxicity with fatal conse-
quences. For example, statin-induced myopathy was shown to be linked to the inhibition of transporter-mediated 
hepatic uptake of statins by the co-administered gemfibrozil or Cyclosporin A8,9. Inhibition of OATP1B function 
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may also result in elevated bilirubin levels10,11. OATP1B expression is often reduced in liver diseases including 
non-alcoholic fatty liver disease, hepatocellular carcinoma, inflammatory cholestasis, primary biliary cirrhosis or 
chronic hepatitis12. OATP2B1 is also expressed in the liver13, though its contribution to the hepatic clearance of 
exogenous compounds is unclear. OATP2B1 was shown to influence the intestinal absorption of orally admin-
istered drugs such as celiprolol, fexofenadine and montelukast5,14. Additionally, OATP2B1 is expressed in skel-
etal muscle and in the heart, mediating the muscular uptake and myotoxicity of statins15. OATP1A2, the fourth 
multispecific member of the OATP family, has a largely overlapping expression pattern with OATP2B1, e.g. in 
the intestine and the blood-brain-barrier5,16. Additionally, OATP1A2 is present in the liver, however in contrast 
to OATP1Bs and 2B1, 1A2 is found in cholangiocytes17. Therefore, although OATP1A2 transports a plethora of 
clinically applied drugs, it is not directly involved in hepatic drug uptake, but rather in the reabsorption of drugs 
from the bile. Based on pre-clinical and clinical data, OATP2B1 and 1A2 are key determinants of the intestinal 
uptake of numerous drugs, including various statins, fexofenadine, sulfasalazine and telmisartan18.
Recent guidelines issued by the US Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) require testing the interaction of new molecular entities with OATP1B1 and 1B319,20, and OATP2B1 and 
OATP1A2 are emerging candidates according to the International Transporter Consortium20. Recommended 
functional assays typically measure the effect of the investigated compounds on the OATP-mediated uptake of 
radioactively labelled compounds7. Typical test substrates of OATP1B and 2B1 include radioactively labelled 
estrone-3-sulphate, estradiol-glucuronide, bromosulphophthalein, a statin or cholecystokinin-8 (1B3)7. Recently, 
several clinically applied drug substrates of OATP1B1 (various statins, fexofenadine, or bosentan) measured by 
HPLC-MS (high-performance liquid chromatography with tandem mass spectrometry) have been shown to be 
applicable as test substrates to predict DDI21. Whereas these indirect assays provide a reliable and sensitive meas-
urement of OATP function, radioactive compounds and MS are usually not compatible with large scale screening 
efforts. Lately, 3H-Rosuvastatin and DHEAS have been demonstrated as in vivo substrates of OATP1Bs in cyno-
molgus monkey22,23, and erlotinib as a potential probe substrate for OATP2B1 applicable in humans24.
Fluorescence-based detection technologies are frequently applied in biological testing, due to their unique 
advantages in setting up homogeneous, sensitive assays in miniaturized formats25. A common feature of drug 
transporters is their wide substrate specificity that also encompasses fluorescent molecules. Indeed, fluorescent 
molecules have been successfully used in in vitro and in vivo transporter assays26. Calcein-AM, originally devel-
oped as a viability dye, was discovered to be a high affinity substrate of several pharmacologically relevant ABC 
transporters27–29. Similarly, Hoechst 33342 and DyeCycle Violet, two nucleotide/DNA binding dyes, are ABCG2 
and ABCB1 substrates that can be used to characterize transporter function30,31. Screening assays based on the 
OATP1B1/3-mediated uptake of fluorescein, fluorescein-methotrexate or various fluorescein derivatives have 
also been developed32–34. The applicability of fluorophores in transporter-based assays depends on several sources 
of potential artefacts, including non-specific protein binding, sequestration within the cell, or quenching by pH or 
intracellular ions. Unlike fluorescein or fluorescein-methotrexate, an ideal OATP test substrate should be mem-
brane impermeable, and its fluorescence should be independent of the intracellular milieu.
Our aim in this study was to expand the scope of currently available fluorescent indicators of hepatic OATPs, 
1B1, 1B3 and 2B1. In particular, we wanted to identify a pH-independent fluorophore with low cell permeability, 
to ensure a high signal to noise ratio and to allow transport measurements at acidic pH levels needed for the opti-
mal activity of OATPs35. Using cell lines engineered to overexpress human OATP1B1, 1B3, or 2B1, we identify a 
series of commercially available cell impermeable dyes as high affinity OATP substrates. We show that a transport 
assay based on the uptake of the best-performing fluorophores is amenable to semi high-throughput screening 
for OATP drug interactions.
Results
Zombie Violet is a novel substrate of human OATPs, 1B1, 1B3 and 2B1. In an effort to identify 
new fluorescent substrate candidates of hepatic OATPs, we searched the literature for dyes showing low mem-
brane permeability and pH independent fluorescence. Based on these characteristics we focused on commercially 
available viability dyes, because these fluorescent molecules do not stain living cells, and therefore are expected 
to show low passive permeability. Recently, we have shown that the OATP-mediated transport of fluorescent 
compounds can be quantitatively monitored in insect cells36. Therefore, first we used this expression system to 
test the contribution of OATP1B1 to the cellular uptake of Zombie Violet™ (ZV, BioLegend), an amine-reac-
tive fluorescent dye used for the labelling of dead cells. To discern staining due to cell death, we counterstained 
the cells with propidium iodide (PI). Whereas in control cells staining with ZV was always accompanied by 
PI-positivity (indicating a loss of membrane integrity), cells expressing the human OATP1B1 transporter were 
distinctly ZV-positive and PI-negative, indicating that ZV cannot penetrate living cells unless OATP1B1 is pres-
ent in the plasma membrane (Fig. 1a). Detailed transport measurements confirmed that the accumulation of ZV 
is due to OATP1B1-mediated uptake, showing saturable (Fig. 1b) and inhibitor-sensitive uptake (Supplementary 
Figure 1a).
Next, we screened ZV against the other, multispecific human OATPs of the liver, 1B3 and 2B1 (Fig. 1c). We 
found that, albeit to a lesser extent, ZV is also transported by OATP1B3 and 2B1. ZV transport was sensitive to 
pH (Fig. 1d), with highest uptake at pH 5.5; and also to inhibitors (Supplementary Figure 1b), indicating that ZV 
is a bona fide OATP1B and 2B1 substrate. Additionally, we found that Live/Dead Green (LDG, Life Technologies), 
also designed to label dead cells, is another substrate of these three OATPs, while in the case of Zombie Green (a 
viability dye from the ZombieTM family), there was no OATP-mediated transport (Fig. 1c).
Establishment of A431 cells with robust OATP1B1, 1B3 or 2B1 expression using viability 
dye-based cell sorting. While the Sf9 system has several advantages, the transient nature of OATP expres-
sion is not compatible with high-throughput screening (HTS). In order to build a stable model system and to test 
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whether OATP1B and 2B1-mediated viability dye uptake can also be observed in human cells, we generated A431 
(human epidermoid carcinoma) cell lines overexpressing OATP1B1, 1B3 or 2B1. The A431 cell line was cho-
sen based on its good adherence necessary for transport measurements in 96 well plates. OATP2B1 was readily 
overexpressed in A431 cells, whereas expression levels of OATP1B1 and 1B3 remained very low despite repeated 
rounds of puromycin selection or lentiviral transduction (Fig. 2a shows OATP protein levels in A431 cells in com-
parison to the levels achieved in insect cells). Consequently, transport of a common OATP1B and 2B1 substrate, 
fluorescein-methotrexate showed weak OATP1B activity compared to OATP2B1 (Fig. 2b). Similarly, convincing 
ZV and LDG uptake could only be observed in A431-OATP2B1 cells (Fig. 2b).
Substrate uptake is proportional to OATP expression/function, and we sought to determine whether subpop-
ulations with increased OATP expression could be identified based on substrate accumulation. Since LDG is well 
tolerated (see Supplementary Figure 2), we sorted highly fluorescent LDG-positive A431-OATP1B1, 1B3 and 2B1 
cells, which were further propagated in cell culture. Stunningly, the sorted cells showed significant OATP expres-
sion and function (Fig. 2c,d), indicating that preferential uptake of LDG allowed the function-based sorting of 
cells with high OATP expression. High expression levels were maintained for at least 2 months (cca. 20 passages) 
without the need of further sorting or selection.
A set of commercially available fluorophores as OATP1B and 2B1 substrates. In addition to ZV 
and LDG, a large panel of spectrally diverse dyes aimed for the detection of dead cells is available commercially 
(Table 1). In order to find out whether these fluorescent dyes are also recognized by OATP1B1, 1B3 and 2B1, we 
monitored their uptake in 96 well plates using the sorted A431 cells. In addition to the viability dyes, we tested the 
transport of two other cell-impermeant fluorescent compounds, Cascade Blue hydrazide (CB) and Alexa Fluor 
405 succinimidyl ester (AF405), intended for use in cell permeability assays and the fluorescent labelling of pro-
teins, respectively. As shown in Fig. 3, we found a robust fluorescent signal in OATP-expressing cells with several 
dyes. Moreover, in the case of ZV, LDG, CB and AF405 the signal intensity highly exceeded that of Fl-MTX, indi-
cating that the newly identified dyes may be better suited for fluorescence-based studies assaying OATP function. 
On the other hand, Zombie Green, Live/Dead Red, Live/Dead Aqua, Live/Dead Yellow, Live/Dead Far-red and 
Live/Dead near-IR were not transported by the investigated OATPs (Table 1).
Figure 1. Uptake of viability dyes in Sf9 cells measured by flow cytometry. (a) Uptake of ZV (0.2 µl in 100 µl) 
was measured at 37 °C in pH 5.5 uptake buffer for 15 minutes. Dead cells were identified based on PI staining. 
Experiments were repeated at least three times, the result of one representative experiment is shown. (b) 
Kinetics of OATP1B1-mediated ZV uptake. Uptake rates were normalized to the fluorescence values measured 
for OATP1B1 incubated with 2 µl ZV for 30 minutes. (c) ZV and LDG uptake in Sf9 cells. Dye (0.2 µl in 100 µl) 
uptake was measured after 30 minutes of incubation. Statistical analysis was performed by Student’s t-test. 
*p < 0.05, ***p < 0.001. (d) pH dependent uptake of ZV in Sf9 cells. Uptake of 0.2 µl ZV in 100 µl at 37 °C 
was measured in buffers with different pH for 10 minutes. (b,c and d) data represent the average of three 
independent experiments ± SD values.
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Functional assay adapted to microplates. In order to find optimal conditions for measuring the uptake 
of the newly identified OATP1B and 2B1 substrates and to choose the best dye that could be applied in a semi 
high-throughput set up, we characterized the kinetics of uptake by A431-OATP1B1, 1B3 and 2B1 cells seeded 
in 96-well plates. We found rapid (t1/2 values around 10–15 minutes, Supplementary Figure 3b) uptake of the 
newly identified fluorescent dye substrates, and most importantly we also observed that incubation/reaction time 
could be prolonged up to 60 minutes without significant “leakage” of the dyes into control cells. The optimum 
condition for OATP1B and 2B1-mediated uptake for all the tested dyes was found to be at pH 5.5 (Fig. 1d, and 
Supplementary Figure 4).
Structural information was available for AF405 (Tris(N,N-diethylethanaminium) 8-[2-(4-{[(2,5-dio
xopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl)-2-oxoethoxy]pyrene-1,3,6-trisulfonate) and CB 
([(3,6,8-trisulfo-1-pyrenyl)oxy]-,1-hydrazide), which were further characterized to determine the kinetic 
parameters of transport (see Supplementary Figure 3 for detailed characterization of ZV, LDV and LDG trans-
port). In comparison to Fl-MTX, AF405 and CB proved to be lower affinity substrates, whereas the Vmax of 
1B1/2B1-mediated CB transport was 2–4 fold higher. 1B3 showed weak CB transport, but AF405 proved to be an 
excellent substrate with cca. 3-fold higher Vmax value as compared to Fl-MTX (Fig. 4). In experiments performed 
at ideal conditions for each dye, we found that the maximum signal (OATP vs. vector control) can be achieved 
Figure 2. Low level of OATP1B expression in A431 cells. (a) Western blot detection of human OATPs 
expressed in insect and A431 cells. Total cell lysates were analysed by Western blot. Control (ctr.) represents 
Sf9 cells expressing an unrelated protein or mock transfected A431 cells. Multiple migratory bands most 
probably represent differently glycosylated forms of OATPs. Figure for OATP1B1 was sliced from the same 
blot, same exposure time. Full-length blots are presented in Supplementary Figure 7. (b) Fl-MTX, LDG and 
ZV uptake in A431 cells. Representative histograms show the uptake of 1 µM Fl-MTX or 0.4 µl LDG or ZV into 
A431 cells before and after sorting. Cells with the highest LDG fluorescence were sorted, and after recovery, 
the cells were again measured for LDG uptake (panel c). Mock transfected control cells are indicated by filled 
histograms. Cells were incubated with the substrates for 15 minutes (Fl-MTX) or 30 minutes (ZV, LDG) at 
37 °C in uptake buffer (pH 5.5) in final volume of 100 µl. Living (PI-negative) cells are shown. (d) LDG sorting 
results in increased expression of OATP1B1, 1B3 and 2B1. OATP expression was determined using whole cell 
lysates (20 μg each) by Western blot. A431 mock transfected cell lysates were used as control. β-actin served 
as an internal control. Experiments were repeated at least twice. One representative blot is shown. Ctr.: mock-
transfected, non: non-sorted, sort: sorted. Multiple migratory bands most probably represent differentially 
glycosylated forms of OATPs. Full-length blots with different exposition times are presented in Supplementary 
Figure 7.
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with ZV for all three OATPs. CB is as good a substrate for OATP1B1 and 2B1 as ZV. In the case of OATP1B3 the 
highest signal was achieved with ZV, LDG and AF405 (activity ratios are summarized in Table 2). Importantly, 
the transport of all novel fluorescent dyes could be inhibited by known inhibitors.
Inhibition assay using Cascade Blue or Alexa Fluor 405 to probe substrates. Next, we tested the 
applicability of the best performing substrates, CB for OATP1B1 and 2B1, and AF405 for OATP1B3 to detect 
OATP drug interactions. We measured the inhibitory effect of four well-known OATP1B and 2B1 interacting 
compounds (Cyclosporin A (CsA), bromosulphophthalein (BSP), taurocholate (TC) and estrone-3-sulphate 
(ES)). All four compounds inhibited CB or AF405 uptake in a concentration dependent manner (Fig. 5). 
Moreover, the IC50 values obtained in the fluorescence-based assays (Table 3) showed perfect agreement with 
results obtained using radioactive substrates, and pilot screens yielded a z-factor above 0.5, suggesting that the 
new, fluorescence-based assays are amenable to HTS detecting OATP1B/2B1 drug interactions (Table 2)37.
Discussion
Testing the interaction between a new molecular entity and OATP1Bs is required at early stages of drug devel-
opment. Several fluorescent OATP1B substrates have already been identified. These substrates are either mol-
ecules with intrinsic fluorescence, mainly fluorescein and its derivatives33,34, or OATP substrates tagged with 
a fluorophore, such as Oregon green/Flutax-2 (1B332), chenodeoxycholyl-(Nε-1 nitrobenz-2-oxa-1,3-2 
diazole)-lysine (CDCA-NBD)38, cholyl-glycylamido-fluorescein (CGamF)39, cholyl-L-lysyl fluorescein (CLF)40, 
fluorescein-methotrexate (Fl-MTX)32 and 8-fluorescein-cAMP (8-FcA)41. Whereas methods based on the uptake 
of fluorescein and fluorescein-methotrexate have been adapted to semi high-throughput (HT) format32,33, due 
to reliability, sensitivity and availability issues, most of these probes are not ideal for large scale OATP drug 
interaction screens34. For example, Gui et al. found that due to its lower transport capacity by OATP1B1, 
Fl-MTX is not suitable for HT OATP1B1 drug interaction screening32. Moreover, in the case of OATP2B1, an 
Distributor Dye Ex/Em optimum (nm) Transported by OATPs in A431 cells
BioLegend
Zombie Green 488/515 —
Zombie Violet 405/423 1B1, 1B3, 2B1
Thermo Fisher (Life Technologies)
Live/Dead Blue 350/450 very weak 1B1, 1B3, 2B1
Live/Dead Aqua 367/526 —
Live/Dead Violet 416/451 1B1, 1B3, 2B1
Live/Dead Yellow 400/575 —
Live/Dead Green 495/520 1B1, 1B3, 2B1
Live/Dead Red 595/615 —
Live/Dead Far-red 650/665 —
Live/Dead near-IR 750/775 —
Alexa Fluor 405 NHS Ester 401/421 1B1, 1B3, 2B1
Cascade Blue Hydrazide 400/419 1B1, 1B3, 2B1
Table 1. List of the fluorescent dyes tested in the current study. All dyes were tested for transport by OATP1B1, 
1B3 and 2B1 expressed in A431 cells in 96-well plates using an Enspire fluorescent plate reader. Transport was 
tested in at least two independent experiments using triplicates. “—”indicates lack of OATP-mediated uptake.
Figure 3. Screening identifies additional fluorescent OATP substrates. Transport was determined in A431 cells 
expressing OATP1B1, 1B3 or 2B1 seeded in 96-well plates. The cells were incubated with 1 µl ZV, LDV, LDG, 
1 µM (or 4 µM for OATP2B1) Fl-MTX or 20 µM CB and AF405 for 30 minutes at 37 °C in buffer with pH 5.5, in 
final reaction volume of 100 µl. Fluorescence was determined using an Enspire fluorescent plate reader. Activity 
was calculated by dividing fluorescence measured in A431-OATP cells with that measured in A431 mock 
transfected cells. Average of at least three independent measurements with triplicates ± SD values are shown.
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emerging candidate in pharmacokinetic studies, no such fluorescence-based large scale screening method has 
been reported.
Here our aim was to identify novel fluorescent OATP1B1, 1B3 and 2B1 substrates. We tested commercially 
available fluorescent molecules showing low passive cellular uptake, high fluorescence quantum yield and pH 
insensitivity. These characteristics are required to achieve high signal to noise ratio, and maximal OATP activity, 
since OATP2B1 functions (almost) exclusively at acidic extracellular pH36,42. Based on these criteria, we chose 
two sets of compounds. First, we tested fluorescent viability dyes (Zombie dyes and the Live/Dead viability dye 
panel) developed to enter only dead cells. Secondly, we selected CB, a commercially available fluorescent dye used 
to investigate membrane permeability.
We found that in OATP1B or 2B1 expressing live insect cells a typical transporter mediated uptake of ZV can 
be observed (Fig. 1). Moreover, a robust OATP-mediated ZV uptake was also confirmed in A431 cells engineered 
to overexpress the OATP transporters (Figs 2 and 3). ZV was designed to label cells with compromised mem-
branes. Indeed, in control Sf9 and A431 cells ZV fluorescence correlated with propidium iodide staining (Fig. 1a 
Figure 4. Kinetics of uptake of CB, AF405 and Fl-MTX in A431 cells overexpressing OATP1B1, 1B3 or 2B1. 
Transport was measured in 96-well plates. Cells were incubated with increasing concentrations of Fl-MTX, CB 
or AF405 in the linear phase of uptake (2.5 minutes for Fl-MTX, 10 minutes (1B1, 2B1) or 15 minutes (1B3) for 
CB, and 15 minutes for AF405). Transport capacity was calculated based on calibration with known amounts 
of the dye. Uptake in A431-OATP cells without background signal (fluorescence in A431-mock cells) is shown. 
Data points indicate average ± SD values obtained in three independent experiments.
Transport ratio compared to control z-factor
1B1 1B3 2B1 1B1 1B3 2B1
Fl-MTX 2.14 ± 0.44 2.49 ± 0.72 1.24 ± 0.16 0.59 0.77 −1.80
Zombie Violet 11.05 ± 2.47 6.03 ± 1.43 14.65 ± 2.47 0.61 0.61 0.71
Live/Dead Violet 2.03 ± 0.59 1.33 ± 0.21 3.50 ± 0.53 0.55 −0.42 0.79
Live/Dead Green 3.82 ± 0.51 6.58 ± 1.73 6.74 ± 2.82 0.84 0.76 0.62
Cascade Blue 10.79 ± 2.46 1.71 ± 0.16 7.31 ± 2.17 0.73 0.26 0.66
Alexa Fluor 405 5.32 ± 1.22 4.65 ± 0.51 5.46 ± 2.46 0.59 0.64 0.57
Table 2. Transport ratio and z-factor determined in A431-OATP cells. A431 cells (seeded in 96-well plates) 
were incubated with the dyes at pH 5.5 for 30 minutes in order to reach maximum fluorescence signal. Data 
were calculated from at least 3 independent measurements. Dyes were applied in the following concentrations/
amounts: Fl-MTX 1 µM (1B1 and 1B3) and 4 µM (2B1); ZV, LDV and LDG 1-1 µl; CB and AF405 10 µM 
(1B1 and 2B1) and 20 µM (1B3). A z-factor above 0.5 is defined as an excellent assay37. Dyes defined as best 
candidates for HTS are indicated in bold.
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and Supplementary Figure 5). However, our results demonstrate that the expression of OATPs results in the 
staining of living (propidium iodide negative) cells, warranting caution in the interpretation of results obtained 
with ZV as a viability dye.
Using the Sf9 expression system we identified another viability dye, Live/Dead Green as an OATP1B and 
2B1 substrate (Fig. 1c). However, further large scale screens required a well-adherent cell line with stable OATP 
expression. Therefore we generated A431 cells with OATP1B1, 1B3 or 2B1 overexpression. Although A431 is not 
routinely used in pharmacological applications, due to its well-adherence it is well suited to microplate based 
assays43. Unexpectedly, only very low levels of OATP1B1 and 1B3 expression could be achieved in this cell line 
(Fig. 2a) and also in HEK293 or MDCKII cells. Enrichment of OATP1B expressing living cells based on antibody 
labelling is not feasible due to the lack of an anti-OATP antibody recognizing an extracellular epitope. Therefore 
we sorted cells based on increased fluorescence associated with OATP1B/2B1mediated LDG uptake, which led 
to the enrichment of OATP1B and 2B1 positive cells characterized by elevated OATP expression and function 
Figure 5. Inhibition of CB and AF405 uptake in A431-OATP cells. Transport of CB (2 µM for OATP1B1 and 
10 µM for OATP2B1) and AF405 (5 µM, OATP1B3) was measured for 30 minutes in the absence or presence 
of the investigated compounds. Transport was determined by subtracting fluorescence in A431-mock cells. 
Transport measured in cells with the dye alone was set to 100% and the effect of the compounds was compared 
to this value. Experiments were performed in triplicates with three parallels in each biological replicate. 
Average ± SD values are shown.
OATP1B1 OATP1B3 OATP2B1
This study Literature data This study Literature data This study Literature data
BSP 0.08 +/− 0.10 0.134,41,45 0.9+/−0.31 0.455, 0.541 1.26+/− 0.56 1.246
CsA 0.07 +/− 0.04
0.134,45
0.18+/−0.05 0.241, 1.244 1.45+/− 0.11 3644
0.241, 1.344
E1S 0.22 +/− 0.004 0.0534,41 9.5+/−0.13 2041 0.56+/− 0.05
TC 11.2 +/− 0.22 934, 1945 14.3+/−0.32 18*56 12.3+/− 0.15 946
Table 3. Comparison of IC50 values with literature data. IC50 (µM) values were determined using 2 or 10 µM CB 
(OATP1B1 or 2B1) or 5 µM AF405 (OATP1B3). For detailed description see Fig. 5. Literature data show IC50 
values obtained in assays using EG, ES, 8-FcA or DCF as probe substrates. When transport inhibition data were 
not available, Km values obtained in direct transport experiments are shown, indicated by *.
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(Fig. 2c,d). The application of a fluorescent dye to enrich OATP-expressing cells is a unique (and to our knowl-
edge the first) tool that allows the generation of cells with high OATP levels.
To validate the reliability of the A431 model, we also tested the uptake of the newly identified fluorescent sub-
strates in HEK293 and MDCKII cells that are routinely used in transporter interaction studies. Results obtained 
in HEK and MDCKII cells overexpressing OATP1B1, 1B3 or 2B1 (Supplementary Figure 6) were fully consistent 
with those obtained in A431 cells, supporting the conclusion that the novel fluorescent dye substrates can be 
applied to characterize OATP1B/2B1 function.
Consistently with studies showing that an acidic extracellular milieu can significantly stimulate 
OATP-mediated transport35,42, we observed transport of the new fluorescent substrates almost exclusively at pH 
6.5–5.5. Whether this is due to chemical changes in the fluorescent molecules at lower pH or an indication of 
proton counter transport, needs further investigation. Importantly, inhibition constants obtained with the novel 
assays at acidic pH are in full harmony with data obtained at neutral pH34,41,44, indicating that the established 
assay conditions are suited for OATP drug interaction screens.
Although the exact transport kinetics (Km and Vmax values) for ZV, LDV and LDG could not be defined 
(the molecular formula of these dyes could not be obtained from the suppliers due to proprietary concerns), 
we were able to determine and compare transport kinetics of CB and AF405 with that of Fl-MTX. Fl-MTX is 
a well-established substrate of OATP1B1 and 1B332, and we have demonstrated previously that Fl-MTX is also 
transported by OATP2B1 when an acidic extracellular environment is generated36. In A431 cells we could con-
firm the OATP2B1-mediated uptake of Fl-MTX, however compared to OATP1Bs, Fl-MTX was found to be a 
poor substrate of OATP2B1 (Figs 2 and 3). In the case of the novel dye substrates, we found that CB is preferen-
tially transported by OATP1B1 and 2B1 as compared to Fl-MTX, while OATP1B3 shows preferential transport of 
AF405 as compared to CB and Fl-MTX (Figs 3 and 4 and Table 2).
Besides the hepatic OATP1Bs and 2B1, OATP1A2 is also an important drug transporter. However, in our 
pilot experiments, we found no detectable transport of Zombie Violet, Cascade Blue or Alexa Fluor 405 by this 
transporter.
Highly fluorescent dyes with low cell permeability and elevated transport by OATPs are ideal candidates for 
the development of a sensitive functional assay. Our results demonstrate that the novel OATP1B and 2B1 sub-
strates and the established A431 model cells can be used to measure OATP function in a low to medium through-
put format. The z-factor for the novel substrates also suggests that ZV, LDV (1B1, 2B1), LDG, CB (1B1, 2B1) and 
AF405 may be applied in large scale drug screening studies (Table 2). Experiments using CB or AF405 as probe 
substrates demonstrate that these dyes are suitable to detect OATP substrate/inhibitor interactions (Fig. 5). The 
IC50 values obtained in our assay are in good agreement with those measured with widely accepted test substrates 
(estrone-3-sulphate or estradiol-glucuronide) (Table 3). It is well known that OATP1Bs and 2B1 have more than 
one substrate binding site. The IC50 values measured for OATP1B1-mediated CB uptake are in harmony with 
those obtained with dichlorofluorescein and tritiated estradiol-glucuronide34,44,45. Therefore the CB assay may 
be a good alternative to test OATP1B1 drug interactions as a substitute to estradiol-glucuronide. Similarly, the 
AF405 and CB assay for OATP1B3 and 2B1, respectively resulted in IC50 values similar to that obtained in assays 
using tritiated estradiol-glucuronide (1B3)44, or estrone-3-sulphate (2B1)44,46 as probe substrates. These results 
again clearly argue that CB and AF405 are good alternatives to these radioactive assays. Interestingly, BSP at 
low concentrations activated CB or AF405 uptake by OATP2B1 or 1B3, respectively. Such an activation by BSP 
has not yet been documented, however the stimulatory effect of one compound to the transport of another is a 
well-known phenomenon (summarized in47). In the case of OATP1B3, progesterone was shown to stimulate 
Fl-MTX32 and epigallocatechin gallate estrone-3-sulphate uptake48. Progesterone has also an activating effect on 
OATP2B1-mediated estrone-3-sulphate and dehydroepiandrosterone sulphate uptake49, and prostaglandin A1, 
testosterone and fendilin on estrone-3-sulphate uptake44,50. One possible explanation may be a co-transport of 
the two molecules, however reciprocal transport has not yet been confirmed in any of these cases, and also needs 
further investigation for the fluorescent dyes and BSP.
In conclusion, we show here that several fluorescent viability dyes and two sulfopyrenes (CB and AF405) are 
high capacity substrates of the multispecific OATP1B and 2B1 transporters. The fluorescence-based transport 
assay measuring the uptake of the best-performing substrates, CB and AF405 open the way to the development of 
sensitive high-throughput assays for the detection of OATP1B/2B1 drug interactions.
Materials and Methods
Materials. Zombie dyes (Violet, Green) were purchased from BioLegend® (San Diego, CA, US). LIVE/
DEAD® Fixable Cell Stain Dye panel, Cascade Blue hydrazide, Alexa Fluor 405 succinimidyl ester were bought 
from Thermo Fischer Scientific (Waltham, MA, US), and fluorescein-methotrexate triammonium salt from 
Biotium (Hayward, CA, US). Restriction endonucleases were from New England Biolabs Ltd. (Ipswitch, MA, 
US). All other materials, if not indicated otherwise, were purchased from Sigma Aldrich, Merck (Budapest, HU).
Generation of plasmid constructs. Generation of baculovirus vectors (pAcUW21-L/OATP and 
pAcUW21-control) was described earlier36. OATP2B1 expressing cells were generated by transposase mediated 
genomic insertion of the OATP2B1 cDNA (BC041095.1, HsCD00378878). Briefly, OATP2B1 cDNA was ampli-
fied (Phusion1 High-Fidelity PCR Kit, NEB, Ipswitch, MA, US) from the vector obtained from Harvard PlasmID 
Repository (Harvard Medical School, Boston, MA, US) by using the following primers: forward 5′: GTAAAT 
GCGGCCGC AA GAATTC GCCACCATGGG ACCCAGGATAGG and reverse 5′ GTACAT GCGGCCGC T 
AAGCTT TCACACTCGGGAATCCTC. The PCR fragment was cloned between the NotI-HindIII sites of the 
pSB-CMV vector51.
OATP1B1 and 1B3 overexpressing cells were generated by lentivirus transduction. The lentivirus based 
pRRL-CMV-MCS-IRES-ΔCD4 vector was generated by replacing the sequence of GFP with a multicloning 
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site of the pRRLSIN.cPPT.PGK-GFP.WPRE (Addgene #12252) plasmid (Didier Trono, Lausanne, Switzerland). An IRES 
was cloned between the PmlI and XbaI sites of the MCS (forward: 5′-ACACGTGTCCGGACTAGTCCACCTTGCC 
TTACACATGAAGAG, reverse: 5′-ATCTAGAATGATCAGCCATATTATCATCGTGTTTTTCAAAG). The plasmid 
also contains a truncated CD4 receptor enabling monitoring of the virus transfection. Truncated CD4 cDNA was PCR 
amplified by the following primers (based on52: 5′-GATTCTAGAGCCACCATGAACCGGGGAGTCCCTTTTAGGC 
and 5′-GTAGTCGACTTAGCGCCTTCGGTGCCGGCAC from the pCMV-SPORT6-CD4 (Harvard Plasmid 
Repository). After digestion with XbaI-SalI enzymes, the PCR fragment was cloned to the corresponding sites of the 
pRRL-CMV-MCS-IRES vector.
The open reading frames OATP1B1 (Gene ID: AB026257) and OATP1B3 (BC141525, HsCD00348132) 
were amplified by HF PCR (Phusion1 High-Fidelity PCR Kit, NEB, Ipswitch, MA, US) from the pAcUW-21-L/
OATP1B1-wt vector and from the plasmid obtained from Harvad PlasmID, respectively, using the following 
primers:
OATP1B1: forward 5′ TATTATTCGAAGCCACCATGGACCAAAATCAACAT, reverse 5′ CATGTAAC 
TAGTTTAACAATGTGTTTCACTATCT.
OATP1B3: forward 5′ ACTAGTTTAAACGCCACCATGGACCAACATCAACAT and reverse 5′ GTACATGCG 
GCCGCACTGCAGTTAGTTGGCAGCAGCATTGTC. After digestion with BstBI and SpeI (OATP1B1) 
or PmeI-PstI (OATP1B3) enzymes the PCR fragments were cloned to the corresponding sites of the 
pRRL-CMV-MCS-IRES-ΔCD4 vector.
The base order of the cDNAs in the final vector constructs was verified by sequencing. Empty vectors without 
the OATP cDNAs, pSB-CMV and pRRLdCD4 were used as negative controls (indicated on the Figures as mock).
Expression in insect cells. Transient expression of human OATP1B1, 1B3 and 2B1 in Sf9 (Spodoptera 
frugiperda) cells was achieved as described earlier36. For transport measurements, Sf9 cells after 36–40 hours post 
infection were used.
Generation of cell lines. A431 cells (ATCC) were transfected with 1 µg plasmid DNA (OATP2B1) + 100 
ng plasmid containing the transposase51,53 using Fugene HD reagent (Promega, Madison, WI, US) according 
to the protocol of the supplier. Puromycin (1 µg/ml) selection was started 48 h later. After 2 weeks of puromycin 
selection the cells were grown in DMEM (Gibco, Thermo Fischer Scientific (Waltham, MA, US)) supplemented 
with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37 °C with 5% 
CO2 and 95% humidity, without puromycin.
OATP1B1 and 1B3 overexpression in A431 cells was achieved by recombinant lentiviruses as described in54. 
HEK 293 T human embryonic kidney cells (1.8 × 106 cells on a Petri dish (6 cm in diameter)) were transfected 
with (6 µg) pRRL-CMV-MCS-IRES-ΔCD4/OATP1B1 or OATP1B3, 2.2 µg pMDG and 4 µg psPax2 vectors54 
using CaPO4 precipitation. The supernatant, containing lentiviral particles was collected 72 h after the transfec-
tion. Transduction of target A431 cells was carried out on 6 well plates. The multiplicity of infection was approx-
imately 1.
Determination of dye uptake. Flow cytometry. In order to determine the uptake of the fluorescent mole-
cules in Sf9 cells, recombinant baculovirus infected cells were collected 36–40 hours post infection. After washing 
in the appropriate buffer (usually uptake buffer pH 5.5, see below) 5 × 105 cells were incubated at 37 °C with the 
appropriate amount of dyes (the exact concentrations/amounts are indicated in the Figure legends) in a final vol-
ume of 100 µl. Transport experiments were carried out in the uptake buffer (125 mM NaCl, 4.8 mM KCl, 1.2 mM 
CaCl2, 1.2 mM KH2PO4, 12 mM MgSO4, 25 mM MES, and 5.6 mM glucose, with the pH adjusted to 8.5, 7.4, 6.5 
or 5.5 using 10 N NaOH or 1 M HEPES). Incubation time was between 1–60 minutes. The reaction was stopped 
by the addition of 1 ml ice-cold phosphate-buffered saline (PBS). The cells were kept on ice until flow cytometry 
analysis. The cellular fluorescence of min. 20,000 live cells was determined using an Attune Acoustic Focusing 
Cytometer (Applied Biosystems, Life Technologies, Carlsbad, CA, US). Dead cells labelled with propidium iodide 
(PI, 1 µg/ml) were excluded. Functional data for each OATP represent the mean of at least 3 independent exper-
iments performed on different days. In the case of A431 cells, cells were collected after trypsinization (0.1% 
trypsin) and the uptake experiments were performed in the same way as described for insect cells (see above). 
Data presented on Figures were generated by the FCS Express software.
Microplate-based assay. For the microplate-based assay, OATP-expressing A431 cells were seeded (6 × 104 cells 
in 200 µl final volume/well) onto 96-well plates and cultured for 16–24 h at 37 °C, 5% CO2. Next day, the super-
natant was removed and the cells were washed 3-times with 200 µl of PBS. When inhibitors were tested, the cells 
were pre-incubated in the presence of inhibitors (solved in DMSO) for 5 min at 37 °C (usually in 50 µl volume). 
The amount of DMSO was kept below 0.5% throughout the study. This amount of the solvent did not influence 
the fluorescence of the dyes. The reaction was started with the addition of 50 µl fluorescent dye (1–40 µM final 
concentration or 0.05 µl–1.2 µl in final volume of 100 µl) and the plate was incubated at 37 °C for 2–30 minutes. 
The reaction was stopped by the addition of 200 µl ice-cold PBS. The supernatant was rapidly removed, and the 
cells were washed 3-times with 200 µl ice-cold PBS. Finally, 200 µl PBS was added to the cells and fluorescence was 
measured at room temperature using an Enspire fluorescent plate reader (Perkin Elmer) at wavelengths indicated 
in Table 1.
Cell sorting. Function-based sorting was carried out based on the Live/Dead Green uptake of A431 cells 
expressing OATP1B1, 1B3 or 2B1. 2–4 × 106 cells were incubated with 0.8–1.2 µl Live/Dead Green in 100 µl of 
transport buffer (sterile filtered), pH 5.5 at 37 °C for 30 minutes. The reaction was stopped by the addition of 1 ml 
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DMEM and the cells were centrifuged at 300 g for 4 minutes. The cell pellet was suspended in 500 µl DMEM. 
Cellular fluorescence was analysed using a BD FACSAria III Cell sorter (BD Biosciences, San Jose, CA, US). Cells 
with the highest fluorescence (see the applied gate (“LDG+”) on Fig. 2) were collected and cultured for further 
analysis. Cells kept in culture for maximum 20 passages were used for the experiments.
Western blot. Whole cell lysates of Sf9 or A431 cells (10–50 µg) were separated on 7.5% Laemmli SDS-PAGE 
gels and transferred onto PVDF membranes. Immunoblotting was performed as described in36. Membranes were 
incubated overnight with OATP-specific antibodies or anti-β-actin antibody (A1978, Sigma). The antibodies 
used for the detection of OATP1B1 and 2B1 were kind gifts from Dr. Bruno Stieger (Department of Clinical 
Pharmacology and Toxicology, University Hospital, 8091 Zurich, Switzerland)55. The antibody raised against 
OATP1B3 (AMAb91231) was purchased from Atlas Antibodies (Stockholm, Sweden). Secondary antibodies used 
were 10,000–20,000x diluted, HRP-conjugated anti-rabbit or anti-mouse antibodies (Jackson ImmunoResearch, 
Suffolk, UK). Luminescence was detected using the Luminor Enhancer Solution kit by Thermo Scientific 
(Waltham, MA, US).
Toxicity measurements. 5 × 103 A431 cells were seeded onto 96-well plates in a final volume of 100 µl DMEM. 
The next day a transport assay was performed at sterile conditions using 0.4 or 1.6 µl Live/Dead Green or Zombie 
Violet, respectively/5 × 105 cells in a 100 µl final volume. After 30 minutes, the cells were washed twice with 
PBS. Finally, 200 µl DMEM was added and the cells were cultured for 144 hours. Viability of the cells was deter-
mined using the PrestoBlue (Thermo Fischer Scientific) assay. Briefly, the medium was removed, and 100 µl 5% 
PrestoBlue in PBS was added to the cells. After incubation for 60 minutes at 37 °C, absorbance was detected at 
583 nm with an Enspire fluorimeter (Perkin Elmer). Cells incubated with the buffer alone served as control. 
Background signal was calculated by absorbance measured in empty wells filled with 5% PrestoBlue.
Data analysis and statistics. Z-factor was calculated as follows: 1 − ((3 × SDnegative control + 3 × SDpositive con-
trol)/(Meanpositive − Mean negative)) based on37. Kinetic parameters of dye uptake or inhibition were analysed by Hill 
fit using the Origin 8.6 software. Statistical significance was calculated by Student’s t-test. The p value for statistical 
significance was set at 0.05 (*), 0.01 (**) or 0.001 (***).
Data availability. The datasets generated during the current study are available from the corresponding 
author.
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